The Fourth Hospital of Hebei Medical University

To investigate the effect of persistent subretinal fluid (SRF) on macular microstructure and visual acuity after surgery for rhegmatogenous retinal detachment (RRD).

RRD patients diagnosed between January 2020 and March 2023 who underwent successful scleral buckling (SB) surgery with SRF present 3 months post-operation were retrospectively analyzed. Patients were divided into short-term absorption (Group A, n = 40) and delayed absorption groups (Group B, n = 50). Data on best corrected visual acuity (BCVA), retinal nerve fiber layer thickness (RNFL), subfoveal choroidal thickness (SFCT), and vascular densities were collected at various time points.

BCVA and SFCT showed a downward trend over time, with Group A exhibiting higher values than Group B at multiple time points (P < 0.05). RNFL also decreased over time, but Group A consistently had higher measurements. The choriocapillary plexus vessel density (CCP-VD) decreased in Group B while showing fluctuations in Group A, with higher values in Group A at 3 and 6 months post-absorption (P < 0.001).

After SB surgery, foveal RNFL increased while SFCT decreased, with the short-term absorption group displaying more significant improvements. Additionally, vessel densities decreased over time, and the delayed absorption group showed more substantial decreases in CCP-VD.

Increased glycolytic activity and immune evasion mechanisms in gastric cancer represent significant impediments to therapeutic advancements. In this study, KAT6A was strikingly upregulated in both gastric cancer tissues and cell lines and was significantly associated with malignant phenotypes and shorter survival periods. We have demonstrated that KAT6A upregulates acetylated histone levels, thereby increasing the transcriptional activity of genes, including HK2, PDL1, and CD47. This consequently promotes elevated glycolytic flux and facilitates immune evasion. Notably, for the first time, we discovered that DEK plays a crucial synergistic role in the activation of H3K27ac by KAT6A and that the knockout of DEK can rescue the related effects of overexpressing KAT6A. Moreover, knockdown of KAT6A and DEK suppressed malignant phenotypes in gastric cancer cells, including proliferation, invasion, and migration, while enhancing macrophage phagocytic function and CD8⁺ T-cell activity. Moreover, combined treatment with KAT6A inhibition and an anti-CD47 agent has excellent therapeutic efficacy. These findings reveal the regulatory mechanism through which KAT6A and DEK cooperate to regulate glycolysis levels and immune escape in gastric cancer and provide therapeutic targets and promising treatment strategies for tumor intervention.

This study aims to investigate the relationship between depression and the risks of breast cancer recurrence and mortality.

This retrospective cohort study included 2667 breast cancer patients hospitalized across four hospitals in China between January 1, 2016, and December 31, 2019, with follow-up until December 31, 2025. We identified patients diagnosed with depressive disorder and collected demographic characteristics, tumor pathological features, and clinical treatment data. Primary outcomes were recurrence and mortality. Multi-variable Cox proportional hazards models were used, adjusting for age, tumor stage, estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor-2 (HER2) status, chemoradiotherapy, surgical method, marital status, and body mass index (BMI).

Among 2667 breast cancer patients, 343 (12.8%) were diagnosed with depression disorder. Multivariable analysis showed depressed patients had 60% higher recurrence risk (HR = 1.60, 95% CI:1.21-2.13) and 70% higher breast cancer-specific mortality risk (HR = 1.70, 95% CI:1.20-2.41). In all ER/PR subgroups, depression consistently increased risks (HR > 1), particularly in HER2-positive patients. A significant interaction existed between radiotherapy and depression on mortality (p =0.017), with elevated risk more evident in patients who received radiotherapy. Across all surgical types, depressed patients consistently showed higher risks.

Breast cancer patients with comorbid depression tend to have inferior clinical outcomes. Future research should explore the underlying mechanisms linking depression to cancer progression and evaluate targeted interventions.